![[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.](/media/k2/items/cache/f41687065406fae6d8ff38f5ee43f226_L.jpg)
[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.
Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study Commentaries: Expert reaction to interim analysis of oral antiviral molnupiravir – Science Media Centre Merck’s antiviral pill reduces hospitalization […]
The post [Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19. appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- Summary: Perioperative Management of Patients Taking Direct Oral Anticoagulants
- Summary: Community-Acquired Pneumonia
- RCT: Twice-Yearly Depemokimab Reduced Exacerbations in Severe Eosinophilic Asthma
- RCT: High-Intensity NPPV Reduced Criteria for Intubation in Acute COPD Exacerbations
- M-A | Routine anaerobic coverage for aspiration pneumonia: limited evidence of benefit
Laissez un commentaire
Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.